Open AccessEvaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas
Author(s) -
Prakirthi Yerram,
Samantha Reiss,
Lisa Modelevsky,
Igor T. Gavrilovic,
Thomas Kaley
Publication year - 2019
Publication title -
journal of neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.256
H-Index - 114
eISSN - 1573-7373
pISSN - 0167-594X
DOI - 10.1007/s11060-019-03266-0
Subject(s) - carmustine , neutropenia , medicine , bevacizumab , lomustine , toxicity , leukopenia , gastroenterology , surgery , chemotherapy , etoposide , cyclophosphamide , vincristine
An increased incidence in hematologic toxicity has been reported with the addition of bevacizumab to lomustine for patients with recurrent or progressive high grade gliomas (HGG). Data regarding incidence of toxicity with combination bevacizumab and carmustine is limited. The purpose of this study is to compare toxicity of single agent carmustine and carmustine plus bevacizumab for patients with HGGs.